Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
Trade-Ideas LLC identified
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Illumina as such a stock due to the following factors:
- ILMN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $169.1 million.
- ILMN has traded 4.3 million shares today.
- ILMN is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ILMN with the Ticky from Trade-Ideas. See the FREE profile for ILMN NOW at Trade-Ideas
More details on ILMN:
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. ILMN has a PE ratio of 123.1. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.
The average volume for Illumina has been 1.1 million shares per day over the past 30 days. Illumina has a market cap of $13.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.09 and a short float of 25.8% with 14.79 days to cover. Shares are up 88.2% year-to-date as of the close of trading on Thursday.
rates Illumina as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 7.0%. Since the same quarter one year prior, revenues rose by 24.8%. This growth in revenue does not appear to have trickled down to the company's bottom line, displaying stagnant earnings per share.
- Net operating cash flow has significantly increased by 62.28% to $83.14 million when compared to the same quarter last year. In addition, ILLUMINA INC has also vastly surpassed the industry average cash flow growth rate of 9.32%.
- ILLUMINA INC reported flat earnings per share in the most recent quarter. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ILLUMINA INC increased its bottom line by earning $1.13 versus $0.62 in the prior year. This year, the market expects an improvement in earnings ($1.77 versus $1.13).
- The gross profit margin for ILLUMINA INC is currently very high, coming in at 74.64%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 8.78% trails the industry average.
- Compared to its closing price of one year ago, ILMN's share price has jumped by 89.77%, exceeding the performance of the broader market during that same time frame. We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
- You can view the full Illumina Ratings Report.